Astrazeneca Plc $AZN Shares Acquired by GC Wealth Management RIA LLC

GC Wealth Management RIA LLC lifted its holdings in shares of Astrazeneca Plc (NYSE:AZN) by 8.8% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 35,401 shares of the company’s stock after purchasing an additional 2,876 shares during the quarter. GC Wealth Management RIA LLC’s holdings in Astrazeneca were worth $3,254,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the business. Triumph Capital Management acquired a new position in Astrazeneca in the third quarter valued at $25,000. Bangor Savings Bank boosted its holdings in Astrazeneca by 102.7% in the fourth quarter. Bangor Savings Bank now owns 304 shares of the company’s stock valued at $28,000 after acquiring an additional 154 shares during the last quarter. Eagle Bay Advisors LLC acquired a new position in Astrazeneca in the fourth quarter valued at $30,000. Rakuten Investment Management Inc. acquired a new position in Astrazeneca in the third quarter valued at $31,000. Finally, YANKCOM Partnership acquired a new position in Astrazeneca in the fourth quarter valued at $31,000. Institutional investors and hedge funds own 20.35% of the company’s stock.

Astrazeneca Price Performance

NYSE:AZN opened at $185.60 on Thursday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 0.72 and a current ratio of 0.94. Astrazeneca Plc has a 12 month low of $132.32 and a 12 month high of $212.71. The stock has a market capitalization of $287.85 billion, a price-to-earnings ratio of 31.97, a P/E/G ratio of 1.42 and a beta of 0.35.

Astrazeneca (NYSE:AZN) last released its quarterly earnings data on Wednesday, April 29th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.53 by $0.05. Astrazeneca had a return on equity of 31.57% and a net margin of 17.41%.The company had revenue of $15.29 billion for the quarter, compared to analyst estimates of $14.74 billion. As a group, equities research analysts predict that Astrazeneca Plc will post 10.27 EPS for the current year.

Astrazeneca Announces Dividend

The company also recently declared a dividend, which was paid on Monday, March 23rd. Investors of record on Friday, February 20th were paid a dividend of $1.595 per share. The ex-dividend date of this dividend was Friday, February 20th. This represents a yield of 156.0%. Astrazeneca’s payout ratio is 74.83%.

Key Astrazeneca News

Here are the key news stories impacting Astrazeneca this week:

• Positive Sentiment: AstraZeneca beat Q1 estimates and reaffirmed its 2026 outlook — Q1 EPS $2.58 vs. $2.53 est.; revenue $15.29B vs. $14.74B est. Management highlighted oncology and rare-disease strength, which underpinned the maintained guidance and explains the positive market reaction. Article Title
• Positive Sentiment: AstraZeneca exercised its option to license PTX-299 from Pinetree Therapeutics (an EGFR bispecific antibody degrader), expanding its oncology pipeline; the option exercise triggers a $25M payment to Pinetree — a sign AZN is investing in next?gen targeted therapies. Article Title
• Positive Sentiment: UK investment: AstraZeneca will invest £300M (~$405M) in UK sites, reinforcing production and R&D capacity and giving political/regulatory goodwill that can support long-term operations. Article Title
• Neutral Sentiment: Analyst and media commentary: bullish analyst pieces and investor decks underline long?term oncology-led growth (Seeking Alpha / MarketBeat coverage), but these are reiterations rather than new catalysts. Article Title
• Neutral Sentiment: Participation in FDA pilot for “real?time” trials with Amgen/AZ could speed development cycles long-term, but this is an early-stage regulatory/operational play without immediate revenue impact. Article Title
• Negative Sentiment: Erste Group trimmed its FY2026 EPS forecast slightly to $10.30 from $10.44 — a minor downgrade that signals some analyst caution despite the beat; the revision is small and sits near consensus ($10.27), so its near-term market impact is limited.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on AZN shares. TD Cowen reiterated a “buy” rating on shares of Astrazeneca in a report on Wednesday, March 18th. Wall Street Zen cut Astrazeneca from a “buy” rating to a “hold” rating in a report on Saturday, April 4th. Barclays reiterated an “overweight” rating on shares of Astrazeneca in a report on Tuesday, January 6th. Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of Astrazeneca in a report on Friday, February 6th. Finally, Morgan Stanley reissued an “overweight” rating on shares of Astrazeneca in a research report on Wednesday, April 8th. Eight analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $102.67.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.